The major focus of Dr. Cetas's laboratory is to understand the effects of subarachnoid hemorrhage on the brainstem and central nervous system and their subsequent role in determining long-term outcomes.
Delayed vasospasm is a common and devastating consequence of subarachnoid hemorrhage (SAH) that is poorly understood with few effective treatments. The aim of Dr. Cetas's laboratory research is to identify a novel biomarker for predicting a patient's risk for developing delayed vasospasm and subsequent neurological deficits, as well as a new potential therapeutic target for the medical prevention of delayed vasospasm. Specifically, preliminary data both in animal models and patients of SAH suggest that a group of potent vasodilator metabolites of arachidonic acid (called epoxyeicosatrienoic acids or simply EETs) are linked to the development of vasospasm and may predict its development after SAH. The reasearchers propose to test the hypothesis that EETs levels after SAH correlate with the development of delayed vasospasm and that polymorphisms in the gene EPHX2 (which regulates the metabolism of EETs) correlate with an individual’s EETs response. They anticipate that individuals whose EETs levels are elevated after SAH will not go on to develop vasospasm. Furthermore, they predict that those individuals who do not elevate their EETs levels after SAH will have a higher frequency of polymorphisms in the EPHX2 gene.
- B.A., St. John’s College, Santa Fe New Mexico 1993
- Ph.D., University of Arizona, Tuscon Arizona 2000
- M.D., University of Arizona, Tucson Arizona 2002
- Neurological surgery, Oregon Health & Science University, 2009
- Skull base surgery, Oregon Health & Science University, 2010
- American Board of Neurological Surgery: certified
Memberships and associations
- American Academy of Neurological Surgeons